Alloy Therapeutics and Tahoe Therapeutics Form Joint Venture to Develop First-in-Class Antibody-Drug Conjugates for Hard-to-Treat Cancers
Tahoe Therapeutics and Alloy Therapeutics announced a jointly seeded venture to develop first-in-class antibody-drug conjugates (ADCs) targeting hard-to-treat cancers. The collaboration combines Tahoe’s AI-driven target discovery platform with Alloy’s advanced ADC engineering and development expertise. Together, the companies aim to accelerate the translation of novel cancer targets into differentiated therapeutic candidates with strong clinical potential. 
Alloy Therapeutics and Tahoe Therapeutics Form Joint Venture to Develop First-in-Class Antibody-Drug Conjugates for Hard-to-Treat Cancers